What is the oPTimize study?

The oPTimize study is for adults who have hypoparathyroidism (HypoPT). The study is investigating a weekly injection, called canvuparatide, to see if it may be able to help increase blood calcium levels and ease symptoms in people living with HypoPT.

You may be eligible for the oPTimize study if you meet the following requirements:

• 18 years of age or older

• Documented diagnosis of chronic HypoPT (it may be related to surgery, genetics, or other reasons) for at least the last 12 months

*Other study requirements apply.

Study participants receive at no cost:

• Potential access to a study medicine (as a once weekly self-injection or caregiver-assisted injection)

• Some study participants will receive placebo for the first 6 months, which has no active ingredients.

These study participants will receive the same study support and monitoring from a healthcare team

as those receiving the study medicine

• All study participants will have access to the study medicine at a later point in the study

• Education about hypoparathyroidism

• The opportunity to help advance hypoparathyroidism research

For more information or to see if this study might be a fit for you, please visit the oPTimize website.

Or please contact our Research Coordinator, Jamie Sigg, RD, CDCES, CRC at 303-321-2644 x 214 or email jsigg@denverendocenter.com